The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Prognostic importance of MRD: results of TOURMALINE-MM4 trial for NDMM
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the results from the multicentre, double-blind, phase III TOURMALINE-MM4 trial (NCT02312258) comparing the proteosome inhibitor ixazomib with placebo in elderly patients with non-transplant newly diagnosed multiple myeloma (NDMM). The prognostic value of undetectable MRD in the setting of pre-maintenance therapy in transplant-ineligible patients was highlighted by the longitudinal MRD assessment during post-induction maintenance therapy. Maintenance treatment with ixazomib following best response to induction can benefit progression-free survival (PFS) in MRD-positive patients. This interview took place during the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition.
